ICON Public Limited Company (IJF) - Total Liabilities

Latest as of September 2025: €7.17 Billion EUR ≈ $8.39 Billion USD

Based on the latest financial reports, ICON Public Limited Company (IJF) has total liabilities worth €7.17 Billion EUR (≈ $8.39 Billion USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

ICON Public Limited Company - Total Liabilities Trend (2016–2024)

This chart illustrates how ICON Public Limited Company's total liabilities have evolved over time, based on quarterly financial data. See ICON Public Limited Company working capital to net assets to evaluate short-term liquidity relative to the company's equity base.

ICON Public Limited Company Competitors by Total Liabilities

The table below lists competitors of ICON Public Limited Company ranked by their total liabilities.

Company Country Total Liabilities
Dpm Metals Inc.
AU:DPM
Australia AU$509.27 Million
99 Speed Mart Retail Holdings Berhad
KLSE:5326
Malaysia RM1.98 Billion
Universal Health Services Inc
NYSE:UHS
USA $8.11 Billion
INPOST S.A UNSP.ADR/1/2
F:6690
Germany €13.73 Billion
NISSAN MOTOR SP. ADR/2
F:NISE
Germany €13.97 Trillion
Zhejiang Crystal Optech Co Ltd
SHE:002273
China CN¥3.44 Billion
United Integrated Services Co Ltd
TW:2404
Taiwan NT$53.22 Billion
HUAYU Automotive Systems Co Ltd
SHG:600741
China CN¥129.68 Billion

Liability Composition Analysis (2016–2024)

This chart breaks down ICON Public Limited Company's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of ICON Public Limited Company.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.06 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.77 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.43 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how ICON Public Limited Company's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for ICON Public Limited Company (2016–2024)

The table below shows the annual total liabilities of ICON Public Limited Company from 2016 to 2024.

Year Total Liabilities Change
2024-12-31 €7.35 Billion
≈ $8.60 Billion
-5.09%
2023-12-31 €7.75 Billion
≈ $9.06 Billion
-10.79%
2022-12-31 €8.69 Billion
≈ $10.16 Billion
-6.80%
2021-12-31 €9.32 Billion
≈ $10.90 Billion
+487.89%
2020-12-31 €1.59 Billion
≈ $1.85 Billion
+22.95%
2019-12-31 €1.29 Billion
≈ $1.51 Billion
+28.95%
2018-12-31 €999.97 Million
≈ $1.17 Billion
+4.64%
2017-12-31 €955.62 Million
≈ $1.12 Billion
+8.51%
2016-12-31 €880.67 Million
≈ $1.03 Billion
--

About ICON Public Limited Company

F:IJF Germany Diagnostics & Research
Market Cap
$11.00 Billion
€9.41 Billion EUR
Market Cap Rank
#2780 Global
#546 in Germany
Share Price
€123.20
Change (1 day)
+0.45%
52-Week Range
€72.94 - €170.30
All Time High
€314.40
About

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical stu… Read more